Meeting
2014 ASCO Annual Meeting
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.
Authors
Michelle Wilson
Department of Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Michelle Wilson , Neesha C. Dhani , Hal W. Hirte , Stephen Welch , Helen Steed , Lainie P. Martin , Stephanie Lheureux , Cristina Martin-Lorente , Helen Mackay , Marcus O. Butler , Lisa Wang , Judy Quintos , Katie Allen , Lynda Roman , John Joseph Wright , Amit M. Oza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01935934
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5629)
DOI
10.1200/jco.2014.32.15_suppl.tps5629
Abstract #
TPS5629
Poster Bd #
402A
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.
First Author: Neesha C. Dhani
Poster
2013 ASCO Annual Meeting
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes.
First Author: Ignace Vergote
First Author: B.J. Rimel
Poster
2022 ASCO Annual Meeting
CaboMain: A phase 2 study of cabozantinib as a maintenance agent in patients with ultra-high risk pediatric solid tumors.
First Author: Nilay Shah